---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-26-000024"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:41:55.645779+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q1 revenue rises 48% to $301.7 million, boosts 2026 guidance

## Summary
- Revenue increased 48% to $301.7M driven by Oncology revenue growth of 36% and Screening revenue surge to $41.6M.
- Net loss per share widened to $0.85 from $0.77; non-GAAP net loss per share improved to $0.45 from $0.49.
- Raised 2026 revenue guidance to $1.30-$1.32B (32-34% growth), up from prior $1.25-$1.28B; Oncology volume growth expected >35%.
- Shield screening tests reached 44,000 in Q1; 2026 Shield volume guidance raised to 230,000-245,000 tests.
- Q1 adjusted EBITDA loss of $58.9M relatively flat; free cash flow burn $71.2M; cash position $1.2B.

## SEC filing metadata
- accession: 0001576280-26-000024
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/0001576280-26-000024-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/gh-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-26-000024
- JSON: https://secwatch.observer/filing/0001576280-26-000024.json
- Plain text: https://secwatch.observer/filing/0001576280-26-000024.txt

## Source-grounded claims
- claim_id: f6bea50e552d915195e1fc2ea277726d84cda978
  claim: Guardant Health, Inc. reported the quarter ended March 31, 2026 results: revenue $301.7 million. Guidance raised.
  evidence_excerpt: March 31, 2026. First Quarter 2026 Financial Highlights For the three-month period ended March 31, 2026, as compared to the same period of 2025: • Reported total revenue of $301.7 million, an increase of 48%, driven by: ◦ Oncology revenue of $205.0 million, an increase of 36%, and approximately 86,000 oncology tests, an increase of 47% ◦ Biopharma & Data revenue
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628026000024/0001576280-26-000024-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.